1.Higuchi K, Hayaishi O. Enzymic formation of D-kynurenine from D-tryptophan. Arch Biochem Biophys. 1967；120（2）:397-403.
2.Najfeld V, Menninger J, Muhleman D, et al. Localization of indoleamine 2,3-dioxygenase gene （INDO） to chromosome 8p12-->p11 by fluorescent in situ hybridization. Cytogenet Cell Genet. 1993；64（3-4）:231-232.
3.Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007；396（1）:203-213.
4.Metz R, Duhadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007；67（15）:7082-7087.
5.van Baren N, Van den Eynde BJ. Tumoral immune resistance mediated by enzymes that degrade tryptophan. Cancer Immunol Res. 2015；3（9）:978-985.
6.Theate I, van Baren N, Pilotte L, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res. 2015；3（2）:161-172.
7.van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol. 2015；6:34.
8.Watcharanurak K, Zang L, Nishikawa M, et al. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon gamma gene transfer on interferon gamma-mediated antitumor activity. Gene Ther. 2014；21（9）:794-801.
9.Prendergast GC, Metz R, Muller AJ, et al. IDO2 in immunomodulation and autoimmune disease. Front Immunol. 2014；5:585.
10.Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res. 2017；10:1178646917691938.
11.Munn DH. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci （Elite Ed）. 2012；4:734-745.
12.Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006；12（4）:1144-1151.
13.Jung KH, LoRusso P, Burris H, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 （IDO1） inhibitor Navoximod （GDC-0919） administered with PD-L1 inhibitor （Atezolizumab） in advanced solid tumors. Clin Cancer Res. 2019；25（11）:3220-3228.
14.de Jong RA, Nijman HW, Boezen HM, et al. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int J Gynecol Cancer. 2011；21（7）:1320-1327.
15.Kurdziel K, Ravizzini G, Croft B, et al. The evolving role of nuclear molecular imaging in cancer. Expert Opin Med Diagn. 2008；2（7）:829-842.
16.Sakurai K, Fujisaki S, Adachi K, et al. Indoleamine 2,3-dioxygenase activity during i131-radioisotope therapy for metastatic thyroid cancer］. Gan To Kagaku Ryoho. 2015；42（10）:1259-1261.
17.Zahm CD, Johnson LE, McNeel DG. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. Cancer Immunol Immunother. 2019；68（10）:1661-1669.
18.Chen JY, Li CF, Kuo CC, et al. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res. 2014；16（4）:410.
19.姜艳丽, 方艳秋, 芦小单, 等. 吲哚胺2,3-双加氧酶在良、恶性卵巢肿瘤中的表达及临床意义. 中国妇幼保健. 2014；（36）:6106-6108.
20.Mills A, Zadeh S, Sloan E, et al. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol. 2018；31（8）:1282-1290.
21.Zhang T, Tan XL, Xu Y, et al. Expression and prognostic value of indoleamine 2,3-dioxygenase in pancreatic cancer. Chin Med J （Engl）. 2017；130（6）:710-716.
22.Wang Y, Yao R, Zhang L, et al. IDO and intra-tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma. J Clin Lab Anal. 2019:e22872.
23.Wainwright DA, Balyasnikova IV, Chang AL, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012；18（22）:6110-6121.
24.Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998；281（5380）:1191-1193.
25.Mellor AL, Chandler P, Lee GK, et al. Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol. 2002；57（1-2）:143-150.
26.Wang Q, Liu D, Song P, Zou MH. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci （Landmark Ed）. 2015；20:1116-1143.
27.Fujigaki H, Yamamoto Y, Saito K. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences. Neuropharmacology. 2017；112（Pt B）:264-274.
28.Lima S, Kumar S, Gawandi V, et al. Crystal structure of the Homo sapiens kynureninase-3-hydroxyhippuric acid inhibitor complex: insights into the molecular basis of kynureninase substrate specificity. J Med Chem. 2009；52（2）:389-396.
29.倪晓琳, 胡润晖, 贺晨, 等. 犬尿氨酸途径代谢酶与肿瘤的研究进展. 重庆医科大学学报. 2017；（11）:1363-1365.
30.Munn DH. Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr Med Chem. 2011；18（15）:2240-2246.
31.Suzuki S, Tone S, Takikawa O, et al. Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti. Biochem J. 2001；355（Pt 2）:425-429.
32.Ciorba MA, Bettonville EE, McDonald KG, et al. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol. 2010；184（7）:3907-3916.
33.Moon YW, Hajjar J, Hwu P, et al. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer. 2015；3:51.
34.Johnson TS, Munn DH. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest. 2012；41（6-7）:765-797.
35.马齐襄, 朱晓丹, 胡凯文, 等. 肿瘤转移的种子与土壤学说新认识. 肿瘤防治研究. 2015；（10）:1049-1053.
36.Bauer TM, Jiga LP, Chuang JJ, et al. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int. 2005；18（1）:95-100.
37.Metz R, Rust S, Duhadaway JB, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012；1（9）:1460-1468.
38.Harding HP, Novoa I, Zhang Y, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000；6（5）:1099-1108.
39.Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005；11（3）:312-319.
40.王翠娟, 尚明, 邵华. 芳香烃受体在肿瘤发生及免疫治疗中的作用. 中华肿瘤防治杂志. 2018；（15）:1126-1130.
41.Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011；478（7368）:197-203.
42.Hao K, Zhou Q, Chen W, et al. Possible role of the ‘IDO-AhR axis in maternal-foetal tolerance. Cell Biol Int. 2013；37（2）:105-108.
43.Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010；329（5997）:1345-1348.
44.Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IDO. Nat Med. 2011；17（9）:1094-1100.
45.Dons EM, Raimondi G, Cooper DK, et al. Induced regulatory T cells: mechanisms of conversion and suppressive potential. Hum Immunol. 2012；73（4）:328-334.
46.Hill M, Tanguy-Royer S, Royer P, et al. IDO expands human CD4+ CD25 high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol. 2007；37（11）:3054-3062.
47.Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002；3（11）:1097-1101.
48.Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004；172（7）:4100-4110.
49.Wood KJ, Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 2006；27（4）:183-187.
50.Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007；117（9）:2570-2582.
51.Pyzer AR, Cole L, Rosenblatt J, et al. Myeloid-derived suppressor cells as effectors of immune suppression in cancer. Int J Cancer 2016；139（9）:1915-1926.
52.Holmgaard RB, Zamarin D, Li Y, et al. Tumor-Expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep 2015；13（2）:412-424.
53.Su C, Zhang P, Liu J, et al. Erianin inhibits indoleamine 2,3-dioxygenase-induced tumor angiogenesis. Biomed Pharmacother. 2017；88:521-528.
54.Wei L, Zhu S, Li M, et al. High indoleamine 2,3-dioxygenase is correlated with microvessel density and worse prognosis in breast cancer. Front Immunol. 2018；9:724.
55.Marti LC, Pavon L, Severino P, et al. Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation. Mem Inst Oswaldo Cruz. 2014；109（1）:70-79.
